World-leading microdosing experts explain what tiny psychedelic doses may do, where evidence is strong or weak, and how expectation, protocol, and safety shape outcomes

Microdosing of psychedelics sits between popular enthusiasm and limited scientific proof. Leading researchers and practitioners focus on whether very small doses of psilocybin or LSD can affect mood, cognition, creativity, focus, and mental health without producing a full psychedelic experience. Current evidence remains mixed. Self-reports often claim benefits such as improved wellbeing, productivity, and emotional balance, while controlled studies more often find modest, inconsistent, or expectation-driven effects. Placebo response, dosing schedules, individual differences, and unclear product strength make interpretation difficult. Safety and context remain central. Tiny doses are not risk-free, especially for people with psychiatric vulnerability, medication interactions, or unreliable drug sources. Better trials, clearer protocols, and stronger harm reduction standards are needed before microdosing can be treated as a settled therapeutic or performance-enhancing practice.